A206650 Stock Overview
EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
EuBiologics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,550.00 |
| 52 Week High | ₩14,500.00 |
| 52 Week Low | ₩6,260.00 |
| Beta | 1.27 |
| 1 Month Change | 6.11% |
| 3 Month Change | 30.92% |
| 1 Year Change | 84.10% |
| 3 Year Change | -53.28% |
| 5 Year Change | 93.85% |
| Change since IPO | 167.26% |
Recent News & Updates
Shareholder Returns
| A206650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.5% | -4.0% | -3.3% |
| 1Y | 84.1% | 0.7% | 1.2% |
Return vs Industry: A206650 exceeded the KR Biotechs industry which returned 0.7% over the past year.
Return vs Market: A206650 exceeded the KR Market which returned 1.2% over the past year.
Price Volatility
| A206650 volatility | |
|---|---|
| A206650 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A206650 has not had significant price volatility in the past 3 months.
Volatility Over Time: A206650's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 291 | Yeong-Ok Baik | www.eubiologics.com |
EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits.
EuBiologics Co., Ltd. Fundamentals Summary
| A206650 fundamental statistics | |
|---|---|
| Market cap | ₩493.96b |
| Earnings (TTM) | -₩13.88b |
| Revenue (TTM) | ₩69.37b |
7.1x
P/S Ratio-35.6x
P/E RatioIs A206650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A206650 income statement (TTM) | |
|---|---|
| Revenue | ₩69.37b |
| Cost of Revenue | ₩35.40b |
| Gross Profit | ₩33.96b |
| Other Expenses | ₩47.84b |
| Earnings | -₩13.88b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -380.72 |
| Gross Margin | 48.96% |
| Net Profit Margin | -20.01% |
| Debt/Equity Ratio | 11.7% |
How did A206650 perform over the long term?
See historical performance and comparison